ACQUISITIONS & MERGERS

Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith: "Our target strategy is to focus on metalloenzymes of significant unmet need and high pharma interest, targets with validated biology that have been challenging to drug due to chemistry limitations that we can solve with our platform."

With SneakPeek, Myriad Genetics now serves women earlier in their pregnancy, providing data-driven genetic insights through their lifetime with the Prequel® non-invasive prenatal screen, Foresight® carrier screen, and MyRisk™ Hereditary Cancer Test with RiskScore® for all ancestries.

With this acquisition, Clinical Microbiomics adds leading expertise in metabolite profiling from MS-Omics to further advance its systems biology platform and help researchers worldwide understand the microbiome and how to impact health and disease.  

“The new Berlin location strengthens our capabilities and resources inside the EU for both packaging and sourcing, including decentralized trials,” said James Lovett, Chief Executive Officer at Myonex.

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Avance Clinical has backing from private equity group Riverside Company for their global expansion program.